Seizures
Welcome,         Profile    Billing    Logout  
 21 Companies   32 Products   32 Products   31 Mechanisms of Action   0 Trials   631 News 


«123456789101112»
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Reducing Seizure Frequency Using Cooling of the Head and Neck (clinicaltrials.gov) -  Jun 30, 2017   
    P2,  N=5, Completed, 
    Active, not recruiting --> Completed No longer recruiting --> Completed
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Role of Hormones in Susceptibility to Seizures in Women With Epilepsy (clinicaltrials.gov) -  Jun 30, 2017   
    P=N/A,  N=50, Completed, 
    No longer recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Serotonin Receptors in Seizure Disorders (clinicaltrials.gov) -  Jun 30, 2017   
    P=N/A,  N=95, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Effects of Enzyme Replacement in Gaucher's Disease (clinicaltrials.gov) -  Jun 30, 2017   
    P=N/A,  N=70, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed
  • ||||||||||  topiramate / Generic mfg.
    Phase classification, Enrollment change, Trial termination:  PEPTO: Preventing Epilepsy After Traumatic Brain Injury With Topiramate (clinicaltrials.gov) -  Jun 27, 2017   
    P,  N=6, Terminated, 
    Recruiting --> Completed Phase classification: P2 --> P | N=90 --> 6 | Recruiting --> Terminated; End of funding and low enrollment
  • ||||||||||  topiramate / Generic mfg.
    Enrollment closed, Trial initiation date, Trial primary completion date, Surgery:  Preventing Brain Injury in Infants With Congenital Heart Disease (clinicaltrials.gov) -  Jun 27, 2017   
    P1,  N=24, Active, not recruiting, 
    Phase classification: P2 --> P | N=90 --> 6 | Recruiting --> Terminated; End of funding and low enrollment Recruiting --> Active, not recruiting | Initiation date: Jun 2011 --> Mar 2011 | Trial primary completion date: Dec 2014 --> Aug 2018
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  People Presenting With Neurocysticercosis in North America (clinicaltrials.gov) -  Jun 15, 2017   
    P=N/A,  N=9, Terminated, 
    Recruiting --> Active, not recruiting | Initiation date: Jun 2011 --> Mar 2011 | Trial primary completion date: Dec 2014 --> Aug 2018 N=200 --> 9 | Recruiting --> Terminated | Trial primary completion date: Jan 2030 --> Jun 2017
  • ||||||||||  progesterone / Generic mfg.
    Enrollment change:  Progesterone vs Placebo Therapy for Women With Epilepsy (clinicaltrials.gov) -  Jun 5, 2017   
    P3,  N=294, Completed, 
    Trial primary completion date: Dec 2017 --> Jun 2018 N=462 --> 294
  • ||||||||||  Enrollment change:  Lactic Acidosis During and After Seizures (clinicaltrials.gov) -  May 4, 2017   
    P=N/A,  N=12, Completed, 
    Recruiting --> Completed N=20 --> 12
  • ||||||||||  Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
    Enrollment change, Monotherapy:  Eslicarbazepine Acetate Monotherapy Long Term Study (clinicaltrials.gov) -  Apr 26, 2017   
    P3,  N=274, Completed, 
    N=20 --> 12 N=348 --> 274
  • ||||||||||  Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
    Trial completion, Monotherapy:  Eslicarbazepine Acetate Monotherapy Long Term Study (clinicaltrials.gov) -  Apr 21, 2017   
    P3,  N=348, Completed, 
    N=348 --> 274 Active, not recruiting --> Completed
  • ||||||||||  Enrollment closed, Phase classification:  Modified Atkins Diet Plus KetoCal for Adult Epilepsy (clinicaltrials.gov) -  Mar 14, 2017   
    P=N/A,  N=80, Active, not recruiting, 
    Active, not recruiting --> Completed | N=30 --> 21 Recruiting --> Active, not recruiting | Phase classification: P2/3 --> PN/A
  • ||||||||||  Trial completion, Phase classification, Enrollment change, Trial primary completion date:  Ketogenic Diet for Refractory Status Epilepticus (clinicaltrials.gov) -  Mar 14, 2017   
    P=N/A,  N=15, Completed, 
    Recruiting --> Active, not recruiting | Phase classification: P2/3 --> PN/A Recruiting --> Completed | Phase classification: P2 --> PN/A | N=20 --> 15 | Trial primary completion date: Nov 2016 --> Mar 2017
  • ||||||||||  levetiracetam / Generic mfg.
    Enrollment closed, Trial primary completion date:  Imaging the Effect of Centrotemporal Spikes and Seizures on Language in Children (clinicaltrials.gov) -  Feb 23, 2017   
    P1,  N=144, Active, not recruiting, 
    Initiation date: Dec 2005 --> Sep 2006 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jun 2017
  • ||||||||||  Phase classification:  Exercise Education for Adults With Seizure Disorders (clinicaltrials.gov) -  Feb 13, 2017   
    P,  N=30, Completed, 
    Completed --> Terminated Phase classification: P=N/A --> P
  • ||||||||||  dexamethasone / Generic mfg., albendazole / Generic mfg., omeprazole / Generic mfg.
    Trial completion, Trial initiation date, Trial primary completion date:  Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients (clinicaltrials.gov) -  Feb 3, 2017   
    P3,  N=110, Completed, 
    Phase classification: P=N/A --> P Recruiting --> Completed | Initiation date: Jul 2007 --> Apr 2006 | Trial primary completion date: Jun 2009 --> Mar 2011
  • ||||||||||  Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
    Trial primary completion date, Monotherapy:  Eslicarbazepine Acetate Monotherapy Long Term Study (clinicaltrials.gov) -  Feb 2, 2017   
    P3,  N=348, Active, not recruiting, 
    Recruiting --> Completed | Initiation date: Jul 2007 --> Apr 2006 | Trial primary completion date: Jun 2009 --> Mar 2011 Trial primary completion date: Jan 2017 --> May 2017
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Exercise Education for Adults With Seizure Disorders (clinicaltrials.gov) -  Jan 30, 2017   
    P=N/A,  N=30, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=50 --> 30 | Trial primary completion date: Dec 2017 --> Jan 2017
  • ||||||||||  Trial primary completion date:  Copeptin in Childhood Epilepsy (clinicaltrials.gov) -  Jan 24, 2017   
    P=N/A,  N=340, Active, not recruiting, 
    Recruiting --> Completed | N=50 --> 30 | Trial primary completion date: Dec 2017 --> Jan 2017 Trial primary completion date: Dec 2016 --> Dec 2015
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Pediatric Epilepsy Study in Subjects 1-24 Months (clinicaltrials.gov) -  Jan 17, 2017   
    P2,  N=197, Completed, 
    Trial primary completion date: Oct 2016 --> Mar 2017 No longer recruiting --> Completed
  • ||||||||||  Trial primary completion date:  Exercise Education for Adults With Seizure Disorders (clinicaltrials.gov) -  Jan 10, 2017   
    P0,  N=50, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
    Trial completion, Enrollment change, Trial primary completion date:  Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA) (clinicaltrials.gov) -  Jan 6, 2017   
    P=N/A,  N=56, Completed, 
    Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | N=300 --> 56 | Trial primary completion date: Dec 2016 --> Sep 2014
  • ||||||||||  Trial completion:  Cardiac Arrhythmias in Epilepsy: the CARELINK-study (clinicaltrials.gov) -  Dec 27, 2016   
    P=N/A,  N=49, Completed, 
    Active, not recruiting --> Completed | N=300 --> 56 | Trial primary completion date: Dec 2016 --> Sep 2014 Active, not recruiting --> Completed
  • ||||||||||  vigabatrin / Generic mfg.
    Enrollment change, Trial termination:  STARS: Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients (clinicaltrials.gov) -  Dec 2, 2016   
    P4,  N=1, Terminated, 
    No longer recruiting --> Completed N=12 --> 1 | Recruiting --> Terminated; Was not possible to enroll sufficient number of subjects to draw any worthwhile conclusions from the study.